share_log

Chardan Capital Initiates Coverage On Xilio Therapeutics With Buy Rating, Announces Price Target of $7

Chardan Capital Initiates Coverage On Xilio Therapeutics With Buy Rating, Announces Price Target of $7

查丹資本以購買評級開始對西里奧治療藥物的覆蓋範圍,宣布目標價格為 7 美元
Benzinga Real-time News ·  2022/12/21 06:22

Chardan Capital analyst Matthew Barcus initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $7.

Chardan Capital分析師馬修·巴庫斯以買入評級啟動對西利奧治療公司(納斯達克:XLO)的報道,並宣佈目標價為7美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論